2027 340B reporting requirements are expected to increase hospitals’ administrative costs
Separate mandates from HRSA, CMS and drug manufacturers likely will add to 340B claims-data reporting costs and make compliance more complicated.
The year 2027 is shaping up to be a time of rising administrative burden for hospitals and other covered entities that participate in the 340B Drug Pricing Program.
Looming issues include the rebate model being piloted by the Health Resources and Services Administration (HRSA), expanding manufacturer demands for claims data, and a new reporting mandate from CMS.
Hospitals thus may need to manage potentially overlapping reporting processes, with distinct formats and deadlines.
HRSA’s 340B rebate pilot shifts purchasing costs to providers
The rebate model is scheduled to take effect Jan. 1, covering 21 of the drugs that are subject to Medicare negotiated prices in 2026 and 2027. Providers are preparing for a system that requires them to pay the wholesale acquisition cost (WAC) before submitting claims data to receive a rebate.
Participating manufacturers are authorized to collect specified pharmacy and medical claims data with which to process rebates.
“There are a lot of operational impacts there, and financially, the concern is that it will really cost providers money because they’re going to have to be chasing these rebates,” said Jeff Davis, JD, a healthcare attorney and 340B expert at Bass, Berry & Sims.
The legal standing of the rebate model remains to be seen after the American Hospital Association (AHA) and other plaintiffs filed litigation in Maine federal court to block it. Last year, the same court halted implementation of a rebate pilot that was scheduled to begin Jan. 1, 2026.
Manufacturers expand 340B claims-data requirements
A growing number of manufacturers requiring claims-data submission by 340B covered entities have moved beyond contract pharmacy arrangements to also include in-house pharmacy drugs and physician-administered drugs.
By September, roughly 15 manufacturers had adopted such requirements in 2026. Manufacturers say they can deny 340B discounts to covered entities that fail to comply.
“In some ways the in-house pharmacy claims-data sharing requirements are a bigger, more significant issue [than the rebate model], at least operationally,” Davis said.
“This is not just drugs dispensed by outpatient pharmacies, but this is also for all the medical claims for all the drugs that are used in the hospital and clinic settings,” Davis noted.
The obligation to submit medical claims is “a brand-new imposition on providers,” he said.
Amgen adds encounter-level data demands
Amgen is pushing even farther in its requirement. Effective Nov. 15, the company expanded its policy beyond pharmacy and medical claims to also seek associated clinical encounter information, including diagnosis and service codes.
The company says the data will help verify eligible settings and coding accuracy, although those functions traditionally have been administered through HRSA’s audit and dispute-resolution framework. HRSA has prohibited the collection of such data in the rebate model.
Obstacles to fulfilling the Amgen requirement seem likely. “The requested encounter elements tied to claim-level detail are not available in any standard business reporting from pharmacy software, EMRs or TPAs [third-party administrators],” according to an Oct. 22 online briefing by the National Association of Community Health Centers.
Hospitals challenge manufacturer reporting policies
The AHA has asked HRSA to stop the manufacturer policies, but to date the agency has not announced any action.
At least one manufacturer, Eli Lilly, has suspended 340B discounts for some hospitals that declined to submit the data. Hospitals responded with litigation, arguing that manufacturers cannot impose additional conditions on federally mandated 340B discounts.
Three lawsuits are known to have been filed, the latest Oct. 27 by five Massachusetts hospitals. One of the plaintiffs, UMass Memorial, said the annualized impact of going without 340B pricing is at least $20 million per year.
Lilly and other manufacturers say the claims information is necessary to prevent diversion and duplicate discounts in the 340B program.
At least 18 states are recognized by one or more of the manufacturers as having statutory protections against mandatory 340B claims-data submissions, thus making covered entities in those states exempt from some of the policies: Arkansas, Colorado, Illinois, Louisiana, Maine, Maryland, Nebraska, New Mexico (only for federally qualified health centers and similar entities), North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Washington and West Virginia.
CMS mandates Part D 340B claims reporting in 2027
In the 2027 final rule for the Medicare Physician Fee Schedule (MPFS), CMS announced that Medicare-enrolled providers and suppliers are required to report Part D 340B claims data to a dedicated repository. Each act of noncompliance could result in revocation of the entity’s Medicare enrollment for up to one year.
The new requirement differs from the rebate model in purpose, legal authority and scope, CMS wrote in the final rule, noting that HRSA’s model applies only to selected drugs. But there will be overlap in reporting with respect to the drugs included in the rebate model.
“CMS will coordinate with HRSA to reduce burden on covered entities as feasible,” the final rule states.
CMS repository covers a broad range of Part D 340B claims
The repository data-submission obligation stems from a requirement in the Inflation Reduction Act for Part D inflation rebate calculations to exclude units of 340B drugs. CMS states that upholding that provision is difficult because the agency lacks access to comprehensive claims-level information indicating Part D prescriptions that were purchased through 340B.
The repository was established in the MPFS rule for 2026 and then opened for use on a voluntary basis starting Oct. 1. It becomes mandatory Jan. 1.
CMS is seeking to determine whether the information can provide a more accurate way to exclude 340B units from Part D inflation rebate calculations, compared with the current methodology. If the agency ultimately decides to make the change, it will issue separate rulemaking.
Part D claims that must be reported under the new system span contract pharmacies, in-house pharmacies, retrospective replenishment arrangements, and drugs for which a 340B discount is available through a contractor or third-party administrator (TPA). The requirement applies to all 340B drugs, not only those that are currently subject to inflation rebates.
TPAs or vendors can undertake the required submission on behalf of a covered entity, but the covered entity is responsible for the completeness and accuracy of the submission. Each submission must be certified by the organization’s CEO, CFO, an individual with equivalent authority to those positions, or a delegate.
First CMS reporting deadline is Sept. 30, 2027
Claims submission to the portal will be quarterly, except for the first submission, which will be due Sept. 30, encompassing the first six months of 2027. That’s an accommodation relative to the proposed rule, which would have required Q1 submission by June 30.
CMS says it will permit corrections and additions to previously submitted claims.